Inozyme Pharma To Present Recently Announced Data From Phase 1/2 Trials Of INZ-701 In Adults With ENPP1 Deficiency And ABCC6 Deficiency (PXE) At Upcom...
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) --
Source: menafn.com
Matt Pera News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Matt Pera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Matt Pera Today - Breaking & Trending Today
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization
Source: eagletribune.com
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April –– Phase 1 tr...
Source: businessinsider.com
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 06, 2024 -- Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal...
Source: marketscreener.com
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
NEW YORK & LONDON--(BUSINESS WIRE)--Nov 14, 2023--
Source: eagletribune.com